[
  {
    "ts": null,
    "headline": "FDA Pushes Back Eylea HD Review; Regeneron Still Gains",
    "summary": "Inspection at Novo Nordisk unit Catalent delays action to Q4 2025, but investors keep faith in Eylea's outlook.",
    "url": "https://finnhub.io/api/news?id=9629f79c927b5ae9cb820fdf4ed027d8db39624c4f672fd72d9c3684964c816d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755725457,
      "headline": "FDA Pushes Back Eylea HD Review; Regeneron Still Gains",
      "id": 136450660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Inspection at Novo Nordisk unit Catalent delays action to Q4 2025, but investors keep faith in Eylea's outlook.",
      "url": "https://finnhub.io/api/news?id=9629f79c927b5ae9cb820fdf4ed027d8db39624c4f672fd72d9c3684964c816d"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=ede81e98a401bb61777e1e282357b8873ab3608bbbe2a900cfeb1e2abfa87859",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755707400,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 136459462,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=ede81e98a401bb61777e1e282357b8873ab3608bbbe2a900cfeb1e2abfa87859"
    }
  },
  {
    "ts": null,
    "headline": "EYLEA HD速 (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension",
    "summary": "TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD速 (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics License Application (sBLA) seeking approval",
    "url": "https://finnhub.io/api/news?id=d0c94de03eb58eb0019a281f46bf9bf3bdf414175f98ab895fbf9c93284fb6d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755703140,
      "headline": "EYLEA HD速 (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension",
      "id": 136437842,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD速 (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics License Application (sBLA) seeking approval",
      "url": "https://finnhub.io/api/news?id=d0c94de03eb58eb0019a281f46bf9bf3bdf414175f98ab895fbf9c93284fb6d1"
    }
  }
]